Ricardo Macarron
Overview
Explore the profile of Ricardo Macarron including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
799
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reis E, Buonpane R, Celik H, Marty C, Lei A, Jobe F, et al.
Blood
. 2024 Sep;
144(22):2336-2348.
PMID: 39255409
Mutations in calreticulin (mutCALR) are the second most common drivers of myeloproliferative neoplasms (MPNs) and yet, the current therapeutic landscape lacks a selective agent for mutCALR-expressing MPNs. Here, we show...
2.
Hummel J, Xiao K, Yang J, Epling L, Mukai K, Ye Q, et al.
J Med Chem
. 2024 Feb;
67(4):3112-3126.
PMID: 38325398
CDK2 is a critical regulator of the cell cycle. For a variety of human cancers, the dysregulation of CDK2/cyclin E1 can lead to tumor growth and proliferation. Historically, early efforts...
3.
Rapiteanu R, Karagyozova T, Zimmermann N, Singh K, Wayne G, Martufi M, et al.
Eur Respir J
. 2020 Feb;
55(5).
PMID: 32060058
No abstract available.
4.
Chakravorty S, Chan J, Greenwood M, Popa-Burke I, Remlinger K, Pickett S, et al.
SLAS Discov
. 2018 Apr;
23(6):532-545.
PMID: 29699447
High-throughput screening (HTS) hits include compounds with undesirable properties. Many filters have been described to identify such hits. Notably, pan-assay interference compounds (PAINS) has been adopted by the community as...
5.
Lu Q, Livi G, Modha S, Yusa K, Macarron R, Dow D
Expert Opin Drug Discov
. 2017 Apr;
12(6):541-552.
PMID: 28388235
The analysis of pharmaceutical industry data indicates that the major reason for drug candidates failing in late stage clinical development is lack of efficacy, with a high proportion of these...
6.
Powell D, Hertzberg R, Macarron R
Methods Mol Biol
. 2016 Jun;
1439:1-32.
PMID: 27316985
HTS remains at the core of the drug discovery process, and so it is critical to design and implement HTS assays in a comprehensive fashion involving scientists from the disciplines...
7.
8.
9.
Macarron R, Banks M, Bojanic D, Burns D, Cirovic D, Garyantes T, et al.
Nat Rev Drug Discov
. 2011 Mar;
10(3):188-95.
PMID: 21358738
High-throughput screening (HTS) has been postulated in several quarters to be a contributory factor to the decline in productivity in the pharmaceutical industry. Moreover, it has been blamed for stifling...
10.
Macarron R, Hertzberg R
Mol Biotechnol
. 2010 Sep;
47(3):270-85.
PMID: 20865348
High throughput screening (HTS) is at the core of the drug discovery process, and so it is critical to design and implement HTS assays in a comprehensive fashion involving scientists...